A Phase 3 interventional study of V503 and GARDASIL in Human Papillomavirus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to female participants aged 9 Years to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-14.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Primary objective:
Secondary objectives:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
Biological: V503
Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
Biological: GARDASIL
Geometric Mean Titers (GMTs) to HPV Types 16 and 18
Serum antibodies to HPV types 16 and 18 were measured with a Competitive Luminex Immunoassay.
Time frame: 4 weeks postdose 3 (Month 7)
GMTs to HPV Types 6 and 11
Serum antibodies to HPV types 6 and 11 were measured with a Competitive Luminex Immunoassay.
Time frame: 4 weeks postdose 3 (Month 7)
Percentage of Participants Who Are Seropositive for HPV Types 6/11/16/18
Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck Units/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24. The percentage of participants who were seropositive according to these cutoffs was assessed.
Time frame: 4 weeks postdose 3 (Month 7)
Percentage of Participants With One or More Adverse Events
An adverse event is defined as any unfavourable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine, is also an adverse event. The percentage of participants with one or more adverse events was assessed.
Time frame: Up to Month 7
Percentage of Participants With One or More Injection-site Adverse Reactions
The percentage of participants with one or more injection-site adverse reactions (solicited or unsolicited) was assessed.
Time frame: Up to 5 days after any vaccination
Percentage of Participants With One or More Systemic Adverse Events
The percentage of participants with one or more systemic adverse events was assessed.
Time frame: Up to 15 days after any vaccination
Percentage of Participants With Maximum Oral Temperature ≥37.8°C
The percentage of participants with maximum oral temperature ≥37.8°C was assessed.
Time frame: Up to 15 days after any vaccination
Percentage of Participants With One or More Serious Adverse Events
A serious adverse event is an adverse event that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, or may jeopardize the participant and may require medical or surgical intervention. The percentage of participants with one or more serious adverse events was assessed.
Time frame: Up to Month 7
A total of 603 participants were screened and 600 were randomized
| Milestone | V503 | GARDASIL |
|---|---|---|
| Started | 300 | 300 |
| Received ≥1 dose | 300 | 300 |
| Completed | 294 | 295 |
| Not completed | 6 | 5 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 |
Serum antibodies to HPV types 16 and 18 were measured with a Competitive Luminex Immunoassay.
| milli Merck Units/mL | V503 | GARDASIL |
|---|---|---|
| HPV Type 16 (n=276, 270) | 6739.5 (6134.5 to 7404.1) | 6887.4 (6220.8 to 7625.5) |
| HPV Type 18 (n=276, 269) | 1956.6 (1737.3 to 2203.7) | 1795.6 (1567.2 to 2057.3) |
Serum antibodies to HPV types 6 and 11 were measured with a Competitive Luminex Immunoassay.
| milli Merck Units/mL | V503 | GARDASIL |
|---|---|---|
| HPV Type 6 (n=273, 261) | 1679.4 (1518.9 to 1856.9) | 1565.9 (1412.2 to 1736.3) |
| HPV Type 11 (n=273, 261) | 1315.6 (1183.8 to 1462.0) | 1417.3 (1274.2 to 1576.5) |
Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck Units/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24. The percentage of participants who were seropositive according to these cutoffs was assessed.
| Percentage of participants | V503 | GARDASIL |
|---|---|---|
| HPV Type 6 (n=273, 261) | 100 (98.7 to 100) | 100 (98.6 to 100) |
| HPV Type 11 (n=273, 261) | 100 (98.7 to 100) | 100 (98.6 to 100) |
| HPV Type 16 (n=276, 270) | 100 (98.7 to 100) | 100 (98.6 to 100) |
| HPV Type 18 (n=276, 269) | 100 (98.7 to 100) | 100 (98.6 to 100) |
An adverse event is defined as any unfavourable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine, is also an adverse event. The percentage of participants with one or more adverse events was assessed.
| Percentage of participants | V503 | GARDASIL |
|---|---|---|
| Percentage of Participants With One or More Adverse Events | 96.0 (87.9 to 94.5) | 93.7 (84.1 to 91.7) |
The percentage of participants with one or more injection-site adverse reactions (solicited or unsolicited) was assessed.
| Percentage of participants | V503 | GARDASIL |
|---|---|---|
| Percentage of Participants With One or More Injection-site Adverse Reactions | 91.6 (87.9 to 94.5) | 88.3 (84.1 to 91.7) |
The percentage of participants with one or more systemic adverse events was assessed.
| Percentage of participants | V503 | GARDASIL |
|---|---|---|
| Percentage of Participants With One or More Systemic Adverse Events | 47.5 (41.7 to 53.3) | 52.0 (46.2 to 57.8) |
The percentage of participants with maximum oral temperature ≥37.8°C was assessed.
| Percentage of participants | V503 | GARDASIL |
|---|---|---|
| Percentage of Participants With Maximum Oral Temperature ≥37.8°C | 6.7 (4.1 to 10.1) | 3.3 (1.6 to 6.0) |
A serious adverse event is an adverse event that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, or may jeopardize the participant and may require medical or surgical intervention. The percentage of participants with one or more serious adverse events was assessed.
| Percentage of participants | V503 | GARDASIL |
|---|---|---|
| Percentage of Participants With One or More Serious Adverse Events | 0.3 | 0.7 |
Collected over All adverse events: up to 15 days after each vaccination; serious adverse events: up to Month 7. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| V503 | — | 1/299 (0.3%) | 280/299 (93.6%) |
| GARDASIL | — | 2/300 (0.7%) | 274/300 (91.3%) |
| Event | V503 | GARDASIL |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/299 | 0/300 |
| Pulmonary vasculitisRespiratory, thoracic and mediastinal disorders | 1/299 | 0/300 |
| Complex partial seizuresNervous system disorders | 0/299 | 1/300 |
| Henoch-Schonlein purpuraSkin and subcutaneous tissue disorders | 0/299 | 1/300 |
| Event | V503 | GARDASIL |
|---|---|---|
| Injection-site painGeneral disorders | 269/299 | 266/300 |
| Injection-site swellingGeneral disorders | 144/299 | 109/300 |
| Injection-site erythemaGeneral disorders | 102/299 | 88/300 |
| HeadacheNervous system disorders | 57/299 | 57/300 |
| PyrexiaGeneral disorders | 22/299 | 17/300 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 16/299 | 17/300 |
| NauseaGastrointestinal disorders | 16/299 | 16/300 |
| NasopharyngitisInfections and infestations | 5/299 | 16/300 |
Randomized participants
| Age, Continuous(Years) | V503 | GARDASIL | Total |
|---|---|---|---|
| Mean | 12.6 ± 1.9 | 12.6 ± 1.9 | 12.6 ± 1.9 |
| Age, Customized(Participants) | V503 | GARDASIL | Total |
|---|---|---|---|
| 9 to 12 years old | 150 | 150 | 300 |
| 13 to 15 years old | 150 | 150 | 300 |
| Sex: Female, Male(Participants) | V503 | GARDASIL | Total |
|---|---|---|---|
| Female | 300 | 300 | 600 |
| Male | 0 | 0 | 0 |
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Feb 2011 to primary completion in Dec 2011, 9 months.
Results were first posted in Aug 2017, 5 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent